Skin Cancer & Melanoma

The SkinJect data set found an overall response rate of approximately 80% for patients with nodular basal cell carcinoma receiving 200 µg of doxorubicin microneedle array.

DecisionDx-Melanoma’s i31-SLNB accurately predicted low nodal positivity and high recurrence-free survival in patients with cutaneous melanoma.

SkinCure Oncology filed a federal lawsuit against CMS and HHS to challenge the elimination of reimbursement for image-guided radiation therapy for nonmelanoma skin cancer.

A clinical clearance rate of 73% was noted among patients with basal cell carcinoma receiving 200 ug of doxorubicin microneedle array.

Explore the latest clinical data and therapeutic strategies for acral, mucosal, and uveal melanomas from Mark B. Faries, MD, FACS.

James Larkin, MD, PhD, highlighted toxicities associated with immune checkpoint inhibitors in melanoma at a recent Physicians Education Resource meeting.

Omid Hamid, MD, presented at the 22nd Annual International Symposium on Melanoma and Other Cutaneous Malignancies on the evolving landscape of perioperative immunotherapy and targeted therapy.

Researchers analyzed postoperative complications and survival outcomes in patients with melanoma who underwent therapeutic lymph node dissection.

Aminolevulinic acid plus red lamp therapy was given an sNDA by the FDA for the treatment of superficial basal cell carcinoma.

Nivolumab improved 9-year recurrence-free survival compared with ipilimumab for resected stage III or IV melanoma in the phase 3 CheckMate 238 trial.

IFx-2.0 showed a clinical benefit in an early phase 1 trial and has now been given orphan drug designation by the FDA for patients with stage IIB to IV cutaneous melanoma.

Intensive surveillance and surgical resection for hepatic metastases from uveal melanoma improved long-term remission in a retrospective study.

Pembrolizumab administered before surgery in patients with desmoplastic melanoma led to high pathologic complete response rates in the SWOG S1512 trial.

A phase 3 trial of iSCIB1+, a novel cancer vaccine, assessing patients with advanced melanoma has been cleared by the FDA.

Updated data from the 5-year analysis of KEYNOTE-942 of mRNA-4157/pembrolizumab in high-risk melanoma showed a maintained benefit.

Investigators are currently assessing treatment with Alpha DaRT among those with recurrent CSCC as part of the ReSTART trial.

Sorafenib improved the median progression-free survival compared with placebo among patients with metastatic uveal melanoma in the STREAM study.

Updated results from the phase 1 CK-301-101 trial support the updated label for cosibelimab in this cutaneous squamous cell carcinoma population.

At 1 and 2 years, the progression-free survival rates were higher with nivolumab plus ipilimumab vs pembrolizumab in patients with cutaneous melanoma.

One patient with metastatic bladder cancer experienced an ongoing metabolic complete response following treatment with aldesleukin/imneskibart.

Biomarker analyses and real-world comparisons to refine patient selection are ongoing in the phase 2 PLUME trial.

The 24-month RFS rates were 95.1%, 81.2%, 69.4%, and 48.4% in patients with stage III melanoma who experienced a pCR, near pCR, pPR, pNR, respectively.

The agency has set a PDUFA date of April 10, 2026, for the decision on RP1 plus nivolumab in patients with previously treated advanced melanoma.

A novel cancer vaccine, IO102-IO103, combined with pembrolizumab, showed promising results in improving PFS for advanced melanoma.

Cemiplimab showed comparable rates of second primary tumors and improved disease-free survival in high-risk cutaneous squamous cell carcinoma patients.